Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

161. Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia

Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia Article Text

Evidence-Based Mental Health2013

162. Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice

Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Article Text

Evidence-Based Mental Health2013

163. Death rate in older people with schizophrenia elevated compared with the general population

Death rate in older people with schizophrenia elevated compared with the general population Death rate in older people with schizophrenia elevated compared with the general population | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Death rate in older people with schizophrenia elevated compared with the general population Article Text Prognosis Death rate in older people with schizophrenia elevated compared with the general population Statistics from Altmetric.com No Altmetric data available for this article. Question Question: How do the death rate

Evidence-Based Mental Health2013

164. Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286) Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | Guidance and guidelines | NICE Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) Technology

National Institute for Health and Clinical Excellence - Technology Appraisals2013

165. The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age

The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age Article Text Prognosis The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age Statistics from Altmetric.com

Evidence-Based Mental Health2013

166. Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population

Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Article Text Prevalence Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general

Evidence-Based Mental Health2013

167. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Article Text Therapeutics Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2013

168. Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics

Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics Article Text Therapeutics Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia

Evidence-Based Mental Health2013

169. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia

Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Article Text Medical comorbidity Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Statistics from Altmetric.com

Evidence-Based Mental Health2013

172. Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia

Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia Vancampfort D, Probst M, Helvik Skjaerven L, Catalan-Matamoros D, Lundvik-Gyllensten A, Gomez-Conesa A, Ijntema R, De Hert M (...) CRD summary The authors cautiously concluded that specific physical therapy interventions resulted in beneficial outcomes for psychiatric symptoms, psychological distress, state anxiety, health-related quality of life and aerobic and muscular fitness. This was a well-conducted review and the authors' conclusions reflect some limitations of the evidence. However, the added value of physical therapy in people with schizophrenia remains unclear. Authors' objectives To evaluate the effectiveness

DARE.2012

173. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Soares (...) antipsychotics for the treatment of schizophrenia in terms of time to all-cause medication discontinuation and all-cause treatment discontinuation rate. Searching MEDLINE, EMBASE, Science Citation Index, The Cochrane Library (Issue 4) and the Cochrane Schizophrenia Group Register were searched from inception to April 2009 for articles in any language. Search terms were reported. Study selection Randomised controlled trials (RCTs) and observational studies that compared olanzapine with any other oral

DARE.2012

174. Flupenthixol versus placebo for schizophrenia.

Flupenthixol versus placebo for schizophrenia. BACKGROUND: Flupenthixol, first made available in the UK in 1965, has been used as a treatment for schizophrenia for decades. OBJECTIVES: To evaluate the absolute clinical effects of flupenthixol for schizophrenia in comparison with placebo. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (August 2011), inspected references of all included or excluded studies for further trials, and contacted authors of trials (...) for additional information. SELECTION CRITERIA: All randomised controlled trials (RCTs) that compared flupenthixol with placebo for adults with schizophrenia or related disorders by any means of diagnosis. Primary outcomes of interest were clinically important change in global state, mental state and behaviour, and adverse effects. DATA COLLECTION AND ANALYSIS: We extracted data from the one included study, discussed any disagreement, documented decisions and contacted the authors of the included study

Cochrane2012

175. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia

Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia 22581236 2012 08 31 2013 07 08 2014 11 14 1535-7228 169 7 2012 Jul The American journal of psychiatry Am J Psychiatry Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. 719-24 10.1176/appi.ajp.2012.11071091 Some 25%–30% of patients with schizophrenia have auditory verbal hallucinations that are refractory to antipsychotic drugs (...) patients with schizophrenia and medication-refractory auditory verbal hallucinations were randomly allocated to receive 20 minutes of active 2-mA tDCS or sham stimulation twice a day on 5 consecutive weekdays. The anode was placed over the left dorsolateral prefrontal cortex and the cathode over the left temporo-parietal cortex. Auditory verbal hallucinations were robustly reduced by tDCS relative to sham stimulation, with a mean diminution of 31% (SD=14; d=1.58, 95% CI=0.76–2.40). The beneficial

EvidenceUpdates2012

176. Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics

Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics NIHR HSC Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic

Health Technology Assessment (HTA) Database.2012

177. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of olanzapine and ziprasidone in the treatment of schizophrenia in USA. The authors concluded that olanzapine was associated with better health outcomes

NHS Economic Evaluation Database.2012

179. Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE)

Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE) Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE) Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2012

180. Antipsychotic drug treatment for elderly people with late-onset schizophrenia.

Antipsychotic drug treatment for elderly people with late-onset schizophrenia. BACKGROUND: Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schizophrenia which seems to differ from earlier onset schizophrenia on a variety of counts including response to antipsychotic drugs. OBJECTIVES: To assess (...) the effects of antipsychotic drugs for elderly people with late-onset schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (January 2010) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant authors of trials for additional information. SELECTION CRITERIA: All relevant randomised controlled trials that compared antipsychotic drugs with other treatments

Cochrane2012